**Core Concept**
The patient's symptoms, including muscle pain, weakness, elevated serum creatine kinase (CK), and renal impairment, are suggestive of statin-induced myopathy, a well-documented side effect of statin therapy. Statins inhibit HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway, leading to a decrease in intracellular cholesterol levels and an increase in the expression of muscle-specific genes, including those involved in muscle contraction and repair.

**Why the Correct Answer is Right**
The patient's presentation is consistent with a diagnosis of rhabdomyolysis, a severe form of statin-induced myopathy characterized by muscle necrosis and the release of intramuscular contents, including CK, into the bloodstream. Elevated serum CK levels, muscle pain, and renal impairment are hallmarks of this condition. The positive urine dipstick analysis for blood, without RBCs on urine microscopy, is consistent with myoglobinuria, a complication of rhabdomyolysis. The statin-induced increase in intramuscular CK activity leads to muscle damage and the release of myoglobin into the bloodstream, which is then excreted in the urine.

**Why Each Wrong Option is Incorrect**
* **Option A:** Fibrates, such as fenofibrate, are a different class of lipid-lowering agents that primarily work by activating peroxisome proliferator-activated receptor-alpha (PPAR-α). While fibrates can cause muscle pain and weakness, they are less commonly associated with rhabdomyolysis and myoglobinuria.
* **Option B:** Omega-3 fatty acids, such as fish oil, are not typically associated with muscle pain, weakness, or rhabdomyolysis. They are often used as adjunctive therapy for dyslipidemia and have a favorable safety profile.
* **Option D:** Bile acid sequestrants, such as cholestyramine, are another class of lipid-lowering agents that work by binding to bile acids in the gut and preventing their reabsorption. While they can cause gastrointestinal side effects, they are not typically associated with muscle pain, weakness, or rhabdomyolysis.

**Clinical Pearl / High-Yield Fact**
Rhabdomyolysis is a potentially life-threatening complication of statin therapy, and prompt recognition and discontinuation of the offending agent are essential to prevent further muscle damage and renal impairment. A serum CK level above 5,000 U/L is often used as a threshold for diagnosing rhabdomyolysis, although the patient's symptoms and clinical context should also be considered.

**Correct Answer:** C. Atorvastatin.